WVP
AXSM icon

Worth Venture Partners’s Axsome Therapeutics AXSM Stock Holding History

Worth Venture Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,500
Closed -$16.7K – 192
2022
Q4 		$16.7K Buy
+25,500
New +$1.52M 0.01% 150

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Worth Venture Partners's AXSM Position: Q1 2019 in Review

Worth Venture Partners sold out of Axsome Therapeutics (AXSM) in Q1 2019, closing a stake of 34,448 shares — an estimated $96K sold.

Worth Venture Partners first reported a position in AXSM in Q3 2018 and held it in 2 quarters. The position peaked at $138K in Q3 2018. 65 funds tracked by Wall St. Rank hold AXSM as of Q1 2019.

  • Worth Venture Partners reported no remaining Axsome Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Worth Venture Partners sold 34,448 Axsome Therapeutics shares in Q1 2019, an estimated $96K.
  • Worth Venture Partners first reported a position in Axsome Therapeutics in Q3 2018 and held it in 2 quarters.
  • Worth Venture Partners's Axsome Therapeutics position peaked at $138K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2019.

Based on Worth Venture Partners's 13F filing for Q1 2019, filed 15 May 2019.